drugset / Trial / NCT01911624
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
RandomizedParallel-groupOpen-label
Summary
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S. aureus by direct thrombin inhibitors is safe and translates into a better outcome of patients with S. aureus bacteremia.
Timeline
- Start
- 2013-01
- Primary completion
- 2016-04
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Argatroban | Small molecule | 0.5 ug/kg | Oral |
| Subject | Argatroban | Small molecule | 1 ug/kg | Oral |
| Subject | Dabigatran | Unknown | 110 mg | Oral |
| Comparator | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |